RESUMEN
Breast cancer (BC) is a heterogenous disease with multiple pathways implicated in its development, progression, and drug resistance. Autophagy, a cellular process responsible for self-digestion of damaged organelles, had been recognized as eminent player in cancer progression and chemotherapeutic resistance. The haploinsufficiency of Beclin 1 (BECN1), autophagy protein, is believed to contribute to cancer pathogenesis and progression. In our study, we investigated the expression of BECN1 in a BC female Egyptian patient cohort, as well as its prognostic role through evaluating its association with disease free survival (DFS) after 2 years follow up and association of tumor clinicopathological features. Twenty frozen female BC tissue samples and 17 adjacent normal tissue were included and examined for the expression levels of BECN1. Although the tumor tissues showed lower expression 0.73 (0-8.95) than their corresponding normal tissues 1.02 (0.04-19.59), it was not statistically significant, p: 0.463. BECN1 expression was not associated with stage, nodal metastasis or tumor size, p:0.435, 0.541, 0.296, respectively. However, statistically significant negative correlation was found between grade and BECN1 mRNA expression in the studied cases, p:0.028. BECN1 expression had no statistically significant association with DFS, P = 0.944. However, we observed that triple negative (TNBC) cases had significantly lower DFS rate than luminal BC patients, p: 0.022, with mean DFS 19.0 months, while luminal BC patients had mean DFS of 23.41 months. Our study highlights the potential role of BECN1 in BC pathogenesis, showing that BECN1 expression correlates with poorer differentiation of BC, indicating its probable link with disease aggressiveness. DFS two years follow up showed that TNBC subtype remains associated with less favorable prognosis.
Asunto(s)
Beclina-1 , Neoplasias de la Mama , Clasificación del Tumor , ARN Mensajero , Humanos , Femenino , Beclina-1/genética , Beclina-1/metabolismo , Neoplasias de la Mama/genética , Neoplasias de la Mama/patología , Persona de Mediana Edad , Adulto , ARN Mensajero/genética , ARN Mensajero/metabolismo , Pronóstico , Regulación Neoplásica de la Expresión Génica , Supervivencia sin Enfermedad , Biomarcadores de Tumor/genética , Anciano , EgiptoRESUMEN
BACKGROUND: Colorectal cancer is one of the most common malignancies in humans. About 20% of the cancer incidence was attributed to infectious agents highlighting the association between infectious agents and the development of cancers. It has been suspected that Cryptosporidium spp. infection may be correlated with colon adenocarcinoma. Aim: investigate the percentage of cryptosporidiosis among colorectal cancer patients. SUBJECTS: 100 patients were recruited from Medical Research Institute, Alexandria University. METHODS: Fresh stool specimens were collected, homogenized and examined using direct wet mount and by permanent staining of faecal smears using Modified ZN staining. Molecular detection by PCR amplification of Cryptosporidium COWP gene. RESULTS: Significantly higher proportion of colorectal cancer patients (32.5%, 42.5%) tested positive by MZN and ELISA respectively compared to only 3.3% and 5% of positive MZN and ELISA among control group. Also, positive PCR was detected among higher proportion of colorectal cancer patients (47.5%) and only 5% of control group. Odds of colorectal cancer is 19 times among positive cases of Cryptosporidium by PCR than those without proven infection by PCR (OR 19.12; 95% CI 4.82-75.99). Comparison of the assessment of Cryptosporidium infection made by two techniques produces a kappa value of 0.770, and .759 respectively between NZN, ELISA and PCR as a gold standard, suggesting a good agreement between the two techniques and PCR. This value of kappa is significantly different from zero, K.770, p<0.001 for MZN and K.759, p<.001 for ELISA. Specificity of MZN (100%) is higher than that of ELISA (96.2%) and both reported higher specificity than sensitivity denoting that both tests are good positive to rule in the presence of infection at 40% prevalence. CONCLUSION: Cryptosporidium infection is significantly higher among cancer colon patients reinforcing that it might be considered as a likely risk factor for the development cancer colon.
Asunto(s)
Adenocarcinoma , Neoplasias del Colon , Criptosporidiosis , Cryptosporidium , Humanos , Criptosporidiosis/complicaciones , Criptosporidiosis/epidemiología , Cryptosporidium/genética , Reacción en Cadena de la PolimerasaRESUMEN
OBJECTIVE: The clinical outcomes of hepatitis C virus (HCV) infection and its sequelae including liver cirrhosis and hepatocellular carcinoma (HCC) are greatly affected by host genetic factors; however, the possible mechanisms are still largely unclear. This work aimed to assess transforming growth factor-ß1 (TGF-ß1), and patatin-like phospholipase domain containing-protein 3 (PNPLA3) genetic variants as risk factors for hepatic fibrosis and hepatocellular carcinoma (HCC) in Egyptian patients with HCV-related liver cirrhosis. METHODS: Seventy HCV-related liver cirrhosis patients (Total cirrhosis) who were divided into two groups; 34 patients with HCC (HCC group), and 36 patients without HCC (LC group) and 20 healthy volunteers (control group) were included. Routine laboratory investigations and imaging studies were determined. TGF-ß1 (Arg25Pro; 915G>C) and PNPLA3 (I148M; C>G) variants were evaluated using real-time polymerase chain reaction (real-time PCR). RESULTS: HCC group showed a significantly higher GG genotype distribution of TGF-ß1 (Arg25Pro) than the LC group (P= 0.008, OR: 7.083, CI 95%: 1.422 - 35.282). The distributions of GG genotype (P= 0.047) and G allele (P= 0.002, OR: 4.395, CI 95%: 1.622 - 11.911) of PNPLA3 (I148M) were significantly higher in total cirrhosis patients than controls. CONCLUSION: TGF-ß1 (Arg25Pro) GG variant may be associated with HCC risk in HCV-related liver cirrhosis patients, while PNPLA3 (I148M) GG variant may be associated with cirrhosis development but not HCC risk in HCV-related liver cirrhosis patients.
Asunto(s)
Aciltransferasas/genética , Carcinoma Hepatocelular/genética , Variación Genética , Hepatitis C/complicaciones , Cirrosis Hepática/genética , Neoplasias Hepáticas/genética , Fosfolipasas A2 Calcio-Independiente/genética , Factor de Crecimiento Transformador beta1/genética , Carcinoma Hepatocelular/virología , Estudios de Casos y Controles , Codón/genética , Egipto , Femenino , Humanos , Cirrosis Hepática/virología , Neoplasias Hepáticas/virología , Masculino , Persona de Mediana Edad , Polimorfismo de Nucleótido Simple , RiesgoRESUMEN
BACKGROUND: The balance of the oxidative state in the body is fundamental for the maintenance of homeostasis. It has been implicated in the onset and progression of several diseases including breast cancer. The way in which the Reactive Oxygen Species (ROS) / antioxidants balance leads to or responds to disease is still controversial. In this study, TAC is used as a reference for the total antioxidant power of the body and Coenzyme Q10 (CoQ10) for its vital importance in cellular antioxidant action and being the only lipid soluble antioxidant synthesized endogenously. Copper and zinc were measured as trace elements reflecting the antioxidant micronutrient profile of the body. METHODS: After approval of the ethical committee, 60 recently diagnosed non-intervened breast cancer patients were recruited from the Medical Research Institute hospital, Alexandria University along with 20 apparently healthy volunteers as control group. Full patient history was taken including breastfeeding history, parity, hormone replacement therapy use, body mass index, pathological examination, metastatic work up results, past medical history and drug use. CA 15-3 and laboratory investigations evaluating blood glucose, kidney and liver functions were performed. Q10 levels were measured by HPLC using a kit from Recipe®. TAC was assayed spectrophotometrically (Biodiagnostics®). Copper and Zinc levels were determined by inductively coupled plasma-optical emission spectrometry. RESULTS: There was a statistically significant increase in the CoQ10, TAC and copper levels in the breast cancer group when compared to the control group. Zinc showed no statistically significant difference between the studied groups. CONCLUSION: Inspite of the fact that a high antioxidant level is usually considered as a favourable state, TAC, CoQ10 and copper levels showed significantly higher levels in the breast cancer group when compared to the control group. It is worth mentioning that the cancer group were all recently diagnosed, non-intervened and showed no signs of metastasis. It is still unclear whether the increased antioxidant levels offer a selective growth advantage to tumor cells over their surrounding normal cells or serve as a protective measure by the body in an attempt to correct the assault triggered by the ROS.
Asunto(s)
Antioxidantes/metabolismo , Neoplasias de la Mama/sangre , Cobre/sangre , Ubiquinona/análogos & derivados , Zinc/sangre , Adulto , Biomarcadores , Estudios de Casos y Controles , Femenino , Humanos , Persona de Mediana Edad , Especies Reactivas de Oxígeno , Ubiquinona/sangreRESUMEN
BACKGROUND: Sclerostin, a Wnt-signalling inhibitor, is an established negative regulator of bone formation. However, data regarding its potential importance in vascular disease are less clear. Common carotid artery media thickness (CIMT) assessment and plaque identification using ultrasound imaging are well-recognized tools for identifying and monitoring atherosclerosis. The aim of the present study is to examine the relationship between serum sclerostin and subclinical atherosclerosis (as evidenced by CIMT). METHODS: This cross-sectional study included 50 subjects with T2DM and 20 subjects as a control group. Multivariable linear regression models were used to assess the association of sclerostin with subclinical atherosclerosis. RESULTS: Serum sclerostin levels in T2DM patients were significantly higher compared to the control group (167.16⯱â¯63.60 versus 85.98⯱â¯23.74â¯pg/ml, Pâ¯<â¯0.0001). A concentration of ≥162.5â¯pg/ml showed a sensitivity of 90% and a specificity of 86.67% to detect an increased risk of subclinical atherosclerosis. Univariate analysis revealed a significant positive correlation between serum sclerostin and CIMT (râ¯=â¯0.635, Pâ¯<â¯0.001). Sclerostin concentrations remained independently associated with CIMT (ßâ¯=â¯63.188 [6.919-119.456], Pâ¯=â¯0.017) after adjusting for age and gender. CONCLUSION: Our data suggest a positive correlation between serum sclerostin level and subclinical atherosclerosis in subjects with type 2 diabetes mellitus.
Asunto(s)
Proteínas Adaptadoras Transductoras de Señales/sangre , Aterosclerosis/sangre , Diabetes Mellitus Tipo 2/complicaciones , Angiopatías Diabéticas/sangre , Adulto , Biomarcadores/sangre , Grosor Intima-Media Carotídeo , Estudios Transversales , Diabetes Mellitus Tipo 2/sangre , Femenino , Humanos , Masculino , Persona de Mediana Edad , Placa Aterosclerótica/diagnóstico por imagen , Factores de Riesgo , Sensibilidad y Especificidad , UltrasonografíaRESUMEN
Abdominal imaging leads to the detection of a large number of renal tumors without the ability to distinguish the type of tumor detected. It is necessary to find a precise way to know the type of tumor to determine the appropriate treatment. The use of urine samples for detecting new biomarkers especially proteins has a great potential. In this work we assessed the proteomic profiling difference in a cohort of Egyptian population with renal neoplasms. Methods: This cohort study was conducted on 85 subjects. They were classified as 40 RCC, 15 benign kidney patients, and 30 healthy controls. Morning urine samples were used for peptidome separation using magnetic beads. Matrix assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS) was applied Using FlexControlTM software. Results: Benign tumors were differentiated from controls by 5 integrated peaks, 12 significant and 2 integrated significant peaks, 17:3,418.8 and 25:4,173.41. While RCC were differentiated from benign by 5 integrated, 28 significant and one integrated significant peak. The RCC group was discriminated from the controls by 5 peaks which were integrated from which 1 was integrated and significant (with mass to charge ratio of 12:3,408.97). The three groups showed protein profiles ranging from 1 to 10 kDa. The external validation was performed for the RCC group versus the control reveled sensitivity of 88.7% and specificity of 73.2% by genetic algorithm. Conclusion: Proteomic approach can be used as a sensitive urinary marker differentiating renal masses in an early diagnostic approach.